KRAS and non-small cell lung carcinoma: In a Phase I clinical trial encompassing various solid tumors, sotorasib displayed a modest 7% response rate in 42 KRAS G12C mCRC patients, contrasting with the higher response rates (up to 32%) observed in other cancer types such as non-small cell lung cancer (NSCLC) [3].